TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00600912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFlipid®
Description: continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-ClinOleic 20%®
Description: continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
Study: NCT03260829

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin C
Description: 25 IU of vitamin C injected intraepidermally for 6-8 visits till eruption achieved

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin C
Description: 25 IU of vitamin C injected intraepidermally for 6-8 visits till eruption achieved
Study: NCT06273514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TECAR
Description: TECAR therapy performs using a WINBACK® 1s device (Daeyang Medical Co. Ltd, South Korea) with a maximum power of 100W. A 500 kHz frequency capacitive electrode is applied directly to the active MTrP in the UT. The closed electrode is placed distally on the arm. Lowpulse modulation use during treatment with half-second pauses. This enables the application of the current directly into the MTrP without enrolling the entire muscle. The single exposure last for 10 min. The current dose participant-dependent and ranged from 40 to 60% (100% = 100 Watts).~Each time, before and after treatment, and 30 days after the first therapy, the following features will be asses: pain intensity, muscle strength, and ROM.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling performs using SOMA needles (25 mm x 0.3 mm). During the therapy, the participant is in a prone position. The affected UT region is disinfect before needling. The taut band localizes between the thumb and index finger of the researcher. The needle within the plastic guide tube is place over the MTrP at the UT. The needle directly inserts into the MTrP. A local twitch response confirms the accuracy of the puncture. Needling performs using Hong's fast in, fast out technique. The needle will be withdrawn if no twitching will observe.
Study: NCT02028767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 2.5 mg
Description: Empagliflozin 2.5 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 mg
Description: Empagliflozin 10 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 500 mg
Description: Metformin 500 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin/Metformin FDC
Description: 12.5 mg Empagliflozin / 500 mg Metformin
Study: NCT03445741

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised treadmill group (%70 VO2 max) (group 1)
Description: An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target heart rate (HR) corresponding to values of 70% VO2max were determined by the submaximal treadmill test. The participants were instructed walking at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port, Washington, NY). During 12 weeks, 3 days in a week and 20 minutes per day walking program was applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised treadmill group (%50 VO2 max) (group 2)
Description: An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target heart rate (HR) corresponding to values of 50% VO2max were determined by the submaximal treadmill test. The participants were instructed walking at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port, Washington, NY). During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECE PEDO pedometer group (%50 VO2 max) (group 3)
Description: Target heart rate (HR) corresponding to values of 50 % VO2max were determined by the submaximal treadmill test. The number of steps taken in a minute corresponding to target HR was determined by a criterion pedometer and group 3 was instructed walking in this step range recorded to ECE PEDO giving audible feedback. During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
Study: NCT03205722

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT03806933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% unpreserved Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% unpreserved Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% unpreserved Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% unpreserved Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% unpreserved Sodium Chloride (NaCl).
Study: NCT01886209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study: NCT00674960

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Study: NCT03855527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: SDF will be applied as a cavity disinfected after atraumatic restorative technique (Antimicrobial effect)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Chlorhexidine will be applied as a cavity disinfected after atraumatic restorative technique (Antimicrobial effect)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Atraumatic Restorative Treatment without Disinfection
Description: Atraumatic Restorative Technique will be performed without cavity disinfection
Study: NCT01906853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Study: NCT04194541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutimed Siltect wound dressing
Description: Wound dressing applied and changed as needed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sorbion Sana multi-star wound dressing
Description: Wound dressing applied and changed as needed.
Study: NCT02411253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-2
Description: Subcutaneous injections of IL2 according to regimen A Subcutaneous injections of IL2 according to regimen B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections of Placebo according to regimen A Subcutaneous injections of Placebo according to regimen B
Study: NCT03263104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum ECGC 13110402
Description: Lactobacillus plantarum ECGC 13110402

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study: NCT00840918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intravenous Lidocaine Group - Lidocaine administered intravenously throughout surgery and during the 24 hours following surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
Study: NCT02618109

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Collection of blood samples
Description: Collection of blood samples

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Collection of blood samples
Description: Collection of blood samples
Study: NCT04057937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT05264311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise program
Description: The Pilates Exercise Program (PEP) (1 h x 2 sessions per week x 2 months) was delivered by one Pilates professional (with a mean of 6.5 years of experience in Pilates). The PEP carried out by Pilates instructor has been published in a previous study \[31\]. The exercises focused on core stability, posture, breathing, flexibility, strength, and muscle control, being the active awareness of the use of trunk muscles to stabilize the pelvic-lumbar region the main approach. The exercises performed were: the hundred, the rolled up, single leg circles with bent leg, spine stretch, rolling like a ball and single leg stretch. Each exercise was performed as follows: 4 repetitions of 30 seconds with 2 minutes of recovery between repetitions. In order to complete the 60 minutes session two exercises: the superman and the double leg bridge were added to the mentioned PEP.
Study: NCT02394171

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Cohesion
Description: See description in arm/group above

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cohesion
Description: See description in arm/group above
Study: NCT01973179

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Radiation therapy with protons
Study: NCT01938209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: seated thoracic manipulation
Description: seated general thoracic spine manipulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supine specific thoracic spine manipulation
Description: supine specific thoracic spine manipulation
Study: NCT04562571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charter & patient information leaflets
Description: Public commitment charter, non-prescription pad, information leaflet in case of antibiotic prescription
Study: NCT02771184

Intervention type: DEVICE
Group type: OTHER
Intervention: Lung Sound Recording System
Description: The lung sounds are recorded over the posterior chest in supine position on an examination table. A foam pad with several lung sound transducers is placed under the back of the subjects. During the recording the subjects wear a nose clip and hold a pneumotachograph with both hands. The subjects are instructed to breath at a certain airflow rate during inspiration, with natural breathing during expiration. Therefore, they receive a real-time feedback for the airflow rate. The airflow signal and the lung sounds from 16 lung sound transducers are recorded simultaneously for 30 seconds.

Intervention type: DEVICE
Group type: OTHER
Intervention: Lung Sound Recording System
Description: The lung sounds are recorded over the posterior chest in supine position on an examination table. A foam pad with several lung sound transducers is placed under the back of the subjects. During the recording the subjects wear a nose clip and hold a pneumotachograph with both hands. The subjects are instructed to breath at a certain airflow rate during inspiration, with natural breathing during expiration. Therefore, they receive a real-time feedback for the airflow rate. The airflow signal and the lung sounds from 16 lung sound transducers are recorded simultaneously for 30 seconds.

Intervention type: DEVICE
Group type: OTHER
Intervention: Lung Sound Recording System
Description: The lung sounds are recorded over the posterior chest in supine position on an examination table. A foam pad with several lung sound transducers is placed under the back of the subjects. During the recording the subjects wear a nose clip and hold a pneumotachograph with both hands. The subjects are instructed to breath at a certain airflow rate during inspiration, with natural breathing during expiration. Therefore, they receive a real-time feedback for the airflow rate. The airflow signal and the lung sounds from 16 lung sound transducers are recorded simultaneously for 30 seconds.
Study: NCT02357355

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UIHC Driving Simulator
Description: This is a driving simulator located in the basement of the hospital. A car will be facing a large video screen of a driving simulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UIHC Driving Simulator
Description: This is a driving simulator located in the basement of the hospital. A car will be facing a large video screen of a driving simulation.
Study: NCT00098514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talotrexin ammonium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talotrexin ammonium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talotrexin ammonium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talotrexin ammonium
Study: NCT04425564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronomic XELOX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Classic XELOX

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples for pharmacological studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples for pharmacological studies
Study: NCT01343550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: creativity group
Description: This is a creativity group intervention. There will be 4 groups. Each group has one session per week. Each session is a duration of two hours.
Study: NCT03330379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracoe Smart CuffmanagerTM
Description: In patients randomly assigned to the continuous adjustment strategy, in addition to standard care, the Tracoe Smart CuffmanagerTM will be connected to the tracheal cuff. Within the 2 days following the inclusion, all the intermittent Pcuff measurements will be collected as well as the incidence of Pcuff manual adjustments
Study: NCT02820779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WILLIS
Description: WILLIS® intracranial stent graft system is composed of the stent, delivery system, cobalt-based alloy stent and PTFE graft. It can effectively shunt the blood flow and keep it off of the aneurysm wall.
Study: NCT02114593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent support program
Description: Parent support program
Study: NCT00908479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leg Exercise Program
Description: Participants will engage in an extra 45-60 minutes per day of self-managed lower extremity homework exercises focused on improving strength, balance and walking ability.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leg Management group
Description: Therapist provides educational information about leg pain, recovery, bone density, and fall risk.
Study: NCT01748929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00709969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: 20mg artemether and 120 mg lumefantrine, tablet, dose based on body weight, 3 days treatment 5 - \< 10kg (BWG 1) = 6 doses of 1 tablet / 10 - \< 15kg (BWG 2) = 6 doses of 1 tablet / 15 - ≤ 25kg (BWG 3) = 6 doses of 2 tablets
Study: NCT00674986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek 360° View Blood Glucose Analysis Tool

Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek Aviva Glucose Meter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Aviva Glucose Meter
Study: NCT01461668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retapamulin
Description: Two times a day for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two times a day for 5 days
Study: NCT02732418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Provera CI
Description: The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Provera CI
Description: The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Provera CI
Description: The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-subQ 104
Description: The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA). Depo-subQ provera 104® (medroxyprogesterone acetate injectable suspension, 104 mg/0.65mL) for subcutaneous injection
Study: NCT02242474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-TNF suspended perioperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-TNFα continued perioperatively
Study: NCT01691066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant Toddler Years PRT
Study: NCT00829257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFA-BDP
Description: HFA-BDP (Qvar) 100ug 2puff b.i.d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Fluticasone propionate Accuhaler 250ug b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Description: Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide
Description: Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d
Study: NCT00098514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talotrexin ammonium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talotrexin ammonium
Study: NCT04797338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synarel, 0.2 Mg/Inh Nasal Spray
Description: Intranasal treatment with Nafarelin inhaler: 200 micrograms twice daily (a total of 400 micrograms/d; Synarel, Pfizer) on the evening after oocyte retrieval, which will be continued up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be stopped.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrofem
Description: A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Utrogestan
Description: A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyprogesterone Caproate
Description: A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
Study: NCT00342316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Conditioning Stem Cell Transplantation
Description: One of the following conditioning regimens:~1. Busulphan (orally or IV), fludarabine~2. Fludarabine, carmustine, melfalan~3. Cyclophosphamide, fludarabine
Study: NCT02701218

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Canalith repositioning procedure
Description: Canalith repositioning procedure; single or multiple cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Canalith repositioning procedure
Description: Canalith repositioning procedure; single or multiple cycles
Study: NCT02263651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quilting suture without drainage
Description: In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (\<2cm) are placed from the skin flaps to the underlying muscle. Minor dimpling is considered acceptable and is expected to resolve. If severe dimpling is observed, stitches are removed and replaced.~Efficiency of quilting suture relies on a rigorous repartition of the sutures with a special attention taken to the obliteration of the largest potential dead spaces and the empty axillary apex.~The skin edges are sutured as stated before for the control group. Closed suction will not be used for draining the pectoral area.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional closure with drainage
Description: The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.~The skin is closed in two layers with absorbable sutures, a deep layer of 2.0 or 3.0 vicryl sutures or equivalent, and a subcuticular closure with absorbable 3.0 or 4.0 Monocryl sutures or equivalent.
Study: NCT04139070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Electroporation in combination with systemically administered bleomycin